What is Septerna?
Based in South San Francisco, CA, Septerna is a biotechnology company dedicated to creating new therapies that target G protein-coupled receptors (GPCRs). Leveraging its proprietary Native Complex Platform, Septerna is actively developing a pipeline of oral small-molecule drug candidates. These candidates are aimed at addressing unmet needs in endocrinology, immunology, inflammation, and metabolic diseases. The company pursues these therapeutic avenues both independently and through strategic partnerships, positioning itself for broad impact across multiple disease areas.
How much funding has Septerna raised?
Septerna has raised a total of $538M across 3 funding rounds:
Series A
$100M
Series B
$150M
Stock Offering
$288M
Series A (2022): $100M with participation from BVF Partners, Third Rock Ventures, Samsara BioCapital, and Invus Financial Advisors
Series B (2023): $150M led by RA Capital Management, Samsara BioCapital, and Third Rock Ventures
Stock Issuance/Offering (2024): $288M supported by Cantor Fitzgerald, Cowen, and Wells Fargo Securities
Key Investors in Septerna
Cantor Fitzgerald
Cantor Fitzgerald, a financial services firm founded in 1945, provides institutional debt, equity sales, trading, investment banking, and real estate private equity services.
Cowen
Cowen, an independent financial services firm established in 1918, offers investment banking, research, and investment management services.
Wells Fargo Securities
Wells Fargo Securities is an investment banking entity operating in the United States, providing a range of financial services.
What's next for Septerna?
The recent major strategic investment of $288M positions Septerna for accelerated growth and pipeline advancement. This capital infusion is expected to fuel the progression of its drug candidates through clinical trials and further enhance its proprietary Native Complex Platform. As a clinical-stage biotechnology company, Septerna's strategic focus will likely involve expanding its research and development capabilities, potentially forging new partnerships, and preparing for future commercialization efforts. The company's trajectory suggests a continued emphasis on innovation within the GPCR therapeutic space.
See full Septerna company page
